My research interests are translational in nature, and focus on thrombosis, coronary artery disease, antiplatelet medications and ‘personalized medicine’. I am studying the effect of variations in the human genome on in- vivo drug response through pharmacogenetic analyses. I am interested in the effects of genomic or epigenetic variations on coronary thrombosis phenotypes, and use of ex-vivo thrombosis assays in risk stratification of patients with coronary artery disease.
Clinical Interests: Coronary artery disease, valvular heart disease, cardiac catheterization, coronary intervention, and transcatheter aortic valve replacement (TAVR).
Dr. Kreutz' research includes clinical trials for patients with coronary artery disease and translational research related to thrombosis, antithrombotic therapies and ‘personalized medicine.’ He conducts pharmacogenetic analyses to study the effects of variations in the human genome on in-vivo drug responses. Dr. Kreutz studies variations in expression of non-coding miRNA and association with coronary and ex-vivo thrombosis phenotypes. In addition, he investigates the utility of thromboelastography and platelet function assays in risk stratification of patients with coronary artery disease.